Bright Minds Biosciences (NASDAQ:DRUG) Price Target Raised to $147.00 at BTIG Research

Bright Minds Biosciences (NASDAQ:DRUG) had its target price boosted by BTIG Research from $72.00 to $147.00 in a research note issued to investors on Tuesday,Benzinga reports. BTIG Research currently has a buy rating on the stock.

DRUG has been the subject of several other research reports. Zacks Research downgraded shares of Bright Minds Biosciences from a “strong-buy” rating to a “hold” rating in a report on Tuesday, December 2nd. Chardan Capital reaffirmed a “buy” rating and issued a $80.00 price target on shares of Bright Minds Biosciences in a research note on Friday, January 2nd. Wall Street Zen upgraded shares of Bright Minds Biosciences from a “sell” rating to a “hold” rating in a research note on Saturday, December 27th. HC Wainwright reissued a “buy” rating and set a $115.00 target price on shares of Bright Minds Biosciences in a report on Tuesday, December 30th. Finally, Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Bright Minds Biosciences in a research note on Monday, December 1st. Seven equities research analysts have rated the stock with a Buy rating and one has given a Hold rating to the company. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $108.75.

Bright Minds Biosciences Stock Performance

Shares of DRUG stock opened at $93.21 on Tuesday. Bright Minds Biosciences has a 1 year low of $23.17 and a 1 year high of $123.75. The firm has a market capitalization of $726.11 million, a PE ratio of -76.40 and a beta of -6.15. The stock has a fifty day moving average of $70.97 and a two-hundred day moving average of $52.62.

Institutional Inflows and Outflows

Several hedge funds have recently added to or reduced their stakes in DRUG. Goldman Sachs Group Inc. acquired a new position in shares of Bright Minds Biosciences in the 1st quarter worth $802,000. Sio Capital Management LLC increased its stake in Bright Minds Biosciences by 0.9% in the 2nd quarter. Sio Capital Management LLC now owns 512,338 shares of the company’s stock worth $13,377,000 after purchasing an additional 4,776 shares in the last quarter. Police & Firemen s Retirement System of New Jersey acquired a new stake in Bright Minds Biosciences during the 2nd quarter worth about $28,000. AdvisorShares Investments LLC lifted its stake in Bright Minds Biosciences by 28.4% during the second quarter. AdvisorShares Investments LLC now owns 14,481 shares of the company’s stock valued at $378,000 after buying an additional 3,200 shares in the last quarter. Finally, Acuta Capital Partners LLC lifted its stake in Bright Minds Biosciences by 75.1% during the third quarter. Acuta Capital Partners LLC now owns 84,875 shares of the company’s stock valued at $5,149,000 after buying an additional 36,401 shares in the last quarter. Institutional investors and hedge funds own 40.52% of the company’s stock.

Bright Minds Biosciences News Summary

Here are the key news stories impacting Bright Minds Biosciences this week:

• Positive Sentiment: Phase 2 BREAKTHROUGH topline results: The company reported positive and statistically significant topline results from the Phase 2 trial of BMB-101 in adult patients with drug‑resistant absence seizures and developmental and epileptic encephalopathies, meeting primary efficacy endpoints with robust seizure reduction and a favorable safety profile — the core clinical news driving investor optimism. Bright Minds Phase 2 Topline Results
• Positive Sentiment: Analyst upgrade/target hike: BTIG Research raised its price target from $72 to $147 and reiterated a Buy rating, signaling that at least one institutional analyst now expects substantially higher upside based on the new clinical data — supporting further bullish sentiment. Benzinga
• Neutral Sentiment: Media amplification and coverage: Multiple outlets (MarketWatch, Investing.com, Business Insider, MSN) broadly reported the positive trial toplines, increasing visibility and likely contributing to higher trading volume; these articles reinforce the message but add no new clinical detail. MarketWatch Coverage
• Neutral Sentiment: Planned investor event: Bright Minds had announced a conference call and webcast to present the topline results, which provided a scheduled forum for management to discuss details and field questions — useful for investors but routine. Conference Call Notice
• Negative Sentiment: US$100 million public offering announced: Bright Minds launched a US$100M equity offering (with an underwriter option for up to an additional 15%), which can be dilutive to existing shareholders and may cap near‑term upside despite the positive clinical news. Investors will watch pricing, use of proceeds, and whether insiders participate. Offering Announcement

Bright Minds Biosciences Company Profile

Bright Minds Biosciences Inc, trading on the NASDAQ under the symbol DRUG, is a clinical-stage biotechnology company focused on developing novel small-molecule therapeutics for mental health and neurodegenerative disorders. The company’s research leverages proprietary chemistry platforms to create serotonin-modulating and neuroprotective compounds derived from psychedelic-inspired structures. Bright Minds aims to address unmet needs in conditions such as major depressive disorder, post-traumatic stress disorder and Alzheimer’s disease through orally administered treatments.

The company’s lead candidate, BMB-101, is an oral 5-HT2A receptor-modulating compound in clinical development for mood and anxiety disorders.